Tag Archives: incretin therapy

For decades, glucagon has been viewed as insulin’s opposite. While insulin lowers blood glucose, glucagon raises it by signaling the liver to release stored sugar into the bloodstream. Because of this, glucagon has traditionally been considered a hormone to suppress in people living with type 2 diabetes. However, modern research …

The rise of highly effective GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment. Medications such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are helping patients achieve levels of weight loss that were previously difficult to attain without bariatric surgery. However, as clinicians celebrate these advances, a …

Everything seems to be working perfectly until it suddenly isn’t. A patient is losing weight steadily, HbA1c levels are improving, and confidence is high during every follow-up visit. Then progress slows. The scale barely changes. Blood sugar readings stop improving. Patients start asking whether the medication has stopped working, while …

What if the biggest missed opportunity in diabetes care is not a new drug, but when we start using it? Early GLP-1 therapy is gaining attention as clinicians rethink traditional treatment timelines. Instead of reserving GLP-1 receptor agonists for later stages, emerging evidence suggests starting sooner may improve outcomes and …

Patients today are more informed than ever, but are they always getting the full picture? With headlines and social media amplifying new findings, counseling patients on GLP-1 therapies has become more complex. Many individuals now ask about benefits beyond glucose control and weight loss, from heart protection to cognitive health. …

Can a therapy improve metabolic health even if the scale does not budge? This question is becoming increasingly relevant as clinicians observe patients benefiting from GLP-1 therapy even without significant weight loss. While weight reduction has long been a primary goal of incretin-based therapies, emerging data suggest that metabolic improvements …

Could taking a pill instead of an injection change how early people begin treatment for type 2 diabetes or obesity? In 2026, these oral GLP-1 medications are gaining attention for their simplified dosing and improved convenience. As newer formulations reduce traditional barriers, clinicians are beginning to rethink when to initiate …

Why do some patients respond dramatically to GLP-1 therapies while others see little benefit? This question is becoming more relevant as GLP-1 receptor agonists gain widespread use in diabetes and weight management. Increasingly, clinicians are encountering cases of reduced response to GLP-1 therapies, where expected glycemic or weight outcomes fail …

The choice between oral GLP-1 and injectable therapy is quickly becoming a central question in type 2 diabetes care. With the arrival of oral semaglutide, clinicians now have more flexibility than ever. But how do you decide between a daily pill and a weekly injection? While both options target the …

Why do some patients experience dramatic weight loss on GLP-1 therapies while others barely see a change? This question highlights growing interest in how patients respond differently to GLP-1 therapies, challenging the idea of “average” outcomes seen in clinical trials. While studies often report impressive results, real-world experiences show a …